- Home
- FLNC vs IMNM Comparison
FLNC vs IMNM Comparison
Compare FLNC & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNC
- IMNM
- Stock Information
- Founded
- FLNC 2018
- IMNM 2006
- Country
- FLNC United States
- IMNM United States
- Employees
- FLNC N/A
- IMNM N/A
- Industry
- FLNC Industrial Machinery/Components
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- FLNC Miscellaneous
- IMNM Health Care
- Exchange
- FLNC Nasdaq
- IMNM Nasdaq
- Market Cap
- FLNC 969.5M
- IMNM 945.8M
- IPO Year
- FLNC 2021
- IMNM 2020
- Fundamental
- Price
- FLNC $7.44
- IMNM $8.99
- Analyst Decision
- FLNC Hold
- IMNM Strong Buy
- Analyst Count
- FLNC 19
- IMNM 8
- Target Price
- FLNC $8.47
- IMNM $24.75
- AVG Volume (30 Days)
- FLNC 4.2M
- IMNM 1.1M
- Earning Date
- FLNC 08-11-2025
- IMNM 11-12-2025
- Dividend Yield
- FLNC N/A
- IMNM N/A
- EPS Growth
- FLNC N/A
- IMNM N/A
- EPS
- FLNC N/A
- IMNM N/A
- Revenue
- FLNC $2,449,087,000.00
- IMNM $12,589,000.00
- Revenue This Year
- FLNC N/A
- IMNM N/A
- Revenue Next Year
- FLNC $21.59
- IMNM $154.73
- P/E Ratio
- FLNC N/A
- IMNM N/A
- Revenue Growth
- FLNC 14.26
- IMNM 16.74
- 52 Week Low
- FLNC $3.46
- IMNM $5.15
- 52 Week High
- FLNC $24.00
- IMNM $16.55
- Technical
- Relative Strength Index (RSI)
- FLNC 50.46
- IMNM 43.08
- Support Level
- FLNC $6.60
- IMNM $9.01
- Resistance Level
- FLNC $8.30
- IMNM $9.63
- Average True Range (ATR)
- FLNC 0.47
- IMNM 0.71
- MACD
- FLNC 0.07
- IMNM -0.07
- Stochastic Oscillator
- FLNC 49.35
- IMNM 16.37
About FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.